A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of locally advanced unresectableNSCLC not eligible for curative surgery and/or definitive radiotherapy with orwithout chemotherapy or metastatic NSCLC (squamous or non squamous)

• No prior systemic therapy for their locally advanced or metastatic NSCLC

• Provides a fresh tumor tissue sample or archival sample collected within 2 yearsprior to screening

• PD-L1-high (TC/TPS >= 50%) tumor

• Measurable disease based on RECIST 1.1, as determined by the investigator

• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

• Adequate Baseline organ function

• Female participants of childbearing potential must use adequate contraception

Exclusion Criteria:

• Presence of Epidermal growth factor receptor (EGFR) mutations, Anaplastic lymphomakinase (ALK) translocations, or other known genomic aberrations or oncogenic drivermutations for which a locally approved targeted therapy is available.

• Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFRand /or ALK translocations mutations that are sensitive to available targetedinhibitor therapy, Any other known genomic aberrations or oncogenic driver mutationsfor which a locally approved targeted therapy is available for first-line treatmentof locally advanced or metastatic NSCLC.

• Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 monthsprior to the first dose of study intervention

• Received prior therapy with any immune checkpoint inhibitors

• Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime

• Has an invasive malignancy or history of invasive malignancy other than the diseaseunder study within the last 5 years (clinical exceptions apply as per protocol)

• Symptomatic, untreated, or actively progressing, brain metastases or anyleptomeningeal disease (regardless of symptomatology, treatment status, orstability)

• Autoimmune disease or syndrome that required systemic treatment within the past 2years

• Receiving systemic steroid therapy <= 3 days prior to first dose of studyintervention or any form of immunosuppressive medication

• Received any live vaccine <= 30 days prior to first dose of study intervention

• Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug inducedpneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis

• History or evidence of cardiac abnormalities

• Current unstable liver or biliary disease

• Severe infection within 4 weeks prior to the first dose of study intervention

• Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis Bsurface antigen, or hepatitis C

• Has advanced, symptomatic, or visceral spread and is considered to be at imminentrisk of life-threatening complications (including, but not limited to, massiveuncontrolled effusions [e.g., pleural, pericardial, peritoneal])

• Is currently participating in or has participated in a study of an investigationaltherapy within 4 weeks prior to the first dose of study intervention

• Has a history of allogeneic tissue/stem cell transplant or solid organ transplant